
    
      This is an open-label, safety and efficacy, escalating dose, single arm study on 9 adult
      subjects (3 cohorts) and 3+3 design will be used. HLA typed patients and potential
      blood-related donors will be screened for comorbidities. Suitably matched or haploidentical
      family donors will be selected according to protocol specified criteria and institutional
      guidelines of participating site.
    
  